Share

December 2013; 3 (6) Practice Across Borders

Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease

GraphicFRANCE

François Tison, Wassilios G. Meissner
First published December 9, 2013, DOI: https://doi.org/10.1212/01.CPJ.0000437017.29917.c9
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
41

Share

Article Information

vol. 3 no. 6 480-481
DOI: 
https://doi.org/10.1212/01.CPJ.0000437017.29917.c9
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published December 9, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. François Tison, MD, PhD and
    2. Wassilios G. Meissner, MD, PhD
  1. François Tison, MD, PhD and
    2. Scientific Advisory Boards:

    1. (1)Novartis, (2)Boehringer-Ingelheim, (3) GlaxoSmithKline, (4) ABBOTT, (5) UCB

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Lundbeck, (2) Novartis, (3) UCB, (4) TEVA

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Addex pharma

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis

    Research Support, Government Entities:

    1. (1) French Ministry of Health PHRC 2011, PI

    Research Support, Academic Entities:

    1. (1) University Hospital Bordeaux

    Research Support, Foundations and Societies:

    1. (1) Michael J. Fox Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Wassilios G. Meissner, MD, PhD
    3. Scientific Advisory Boards:

    1. ANM GmbH, Cologne, Germany (2012); Novartis France

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaking fees from Novartis, TEVA Lundbeck, ExpressionSantÏ¿½ and UCB; travel grants from Novartis, GSK, UCB andTEVA/Lundbeck

    Editorial Boards:

    1. Journal of Neural Transmission, member editorial board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Speaking fees from Novartis, TEVA Lundbeck, ExpressionSantÏ¿½ and UCB; travel grants from GSK, Novartis, UCB andTEVA/Lundbeck

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Unrestricted research grants from Novartis, TEVA/Lundbeck

    Research Support, Government Entities:

    1. French Ministry of Health, University Hospital Bordeaux,PSP-France and APTES

    Research Support, Academic Entities:

    1. University Hospital Bordeaux and University Bordeaux

    Research Support, Foundations and Societies:

    1. Michael J Fox Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. for the French Parkinson's Disease Expert Centers; Service de Neurologie, CHU de Bordeaux, Pessac, France; Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France:
  1. Correspondence to:
    francois.tison{at}chu-bordeaux.fr
View Full Text

Article usage

Article usage: November 2013 to July 2022

AbstractFullPdfSource
Nov 2013040Highwire
Dec 20138968Highwire
Jan 201414601Highwire
Feb 20146222Highwire
Mar 20143305Highwire
Apr 20143802Highwire
May 20142300Highwire
Jun 20143301Highwire
Jul 20141700Highwire
Aug 2014801Highwire
Sep 20142603Highwire
Oct 2014600Highwire
Nov 2014312Highwire
Dec 2014810Highwire
Jan 2015400Highwire
Feb 2015701Highwire
Mar 20151701Highwire
Apr 20152313Highwire
May 20151100Highwire
Jun 2015200Highwire
Jul 2015500Highwire
Aug 2015400Highwire
Sep 2015500Highwire
Oct 20151500Highwire
Nov 20153400Highwire
Dec 20153600Highwire
Jan 20165001Highwire
Feb 20161500Highwire
Mar 2016901Highwire
Apr 20161100Highwire
May 20161800Highwire
Jun 20162800Highwire
Jul 20161300Highwire
Aug 20162400Highwire
Sep 20161200Highwire
Oct 20161300Highwire
Nov 20161910Highwire
Dec 20161600Highwire
Jan 20171400Highwire
Feb 2017800Highwire
Mar 2017700Highwire
Apr 2017500Highwire
May 2017500Highwire
Jun 2017501Highwire
Jul 20171000Highwire
Aug 2017400Highwire
Sep 2017600Highwire
Oct 2017600Highwire
Nov 2017700Highwire
Dec 2017400Highwire
Jan 2018400Highwire
Feb 20181710Highwire
Mar 20182300Highwire
Apr 2018800Highwire
May 20181200Highwire
Jun 20181900Highwire
Jul 20182000Highwire
Aug 20184611Highwire
Aug 2018473pmc
Sep 20182300Highwire
Oct 20181800Highwire
Nov 20182200Highwire
Dec 20182800Highwire
Jan 20191600Highwire
Feb 20191300Highwire
Mar 2019700Highwire
Apr 2019500Highwire
May 20191700Highwire
Jun 20191100Highwire
Jul 2019400Highwire
Aug 2019800Highwire
Sep 2019600Highwire
Oct 2019400Highwire
Nov 2019901Highwire
Dec 2019300Highwire
Jan 2020500Highwire
Feb 2020800Highwire
Mar 2020400Highwire
Apr 2020800Highwire
May 2020700Highwire
Jun 20201200Highwire
Jul 2020300Highwire
Aug 2020900Highwire
Sep 20201510Highwire
Oct 2020800Highwire
Nov 2020800Highwire
Dec 2020500Highwire
Jan 2021600Highwire
Feb 2021700Highwire
Mar 20211100Highwire
Apr 20211000Highwire
May 2021900Highwire
Jun 2021900Highwire
Jul 20211501Highwire
Aug 20211500Highwire
Sep 2021800Highwire
Oct 20211001Highwire
Nov 20211800Highwire
Dec 20211200Highwire
Jan 20221900Highwire
Feb 20221600Highwire
Mar 20221200Highwire
Apr 20221500Highwire
May 2022600Highwire
Jun 20221100Highwire
Jul 2022201Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me